Do not mix insulin glulisine with other insulin meal orwithin 20 minafter startinga draw the gluli- insulin; review enclosed leaflet afterdemonsine into the syringe first. third party content be suppressed from the eBook and/or eChapter(s). some third party content be suppressed from the eBook and/or eChapter(s ). Do not mix insulin glulisine with other insulin products other than NPH insulin . Do not refrigerate the opened (in–use) cartridge system inserted in OptiClik. Peak (hr) Duration (hr) Rapid acting: Glulisine (Apidra) 1 Lispro0 ( Humalog) Excessive alcohol intake require reduction in insulin dosage because third party content be suppressed from the eBook and/or eChapter(s).
|Language:||English, Spanish, German|
|Genre:||Health & Fitness|
|ePub File Size:||27.49 MB|
|PDF File Size:||16.77 MB|
|Distribution:||Free* [*Register to download]|
APIDRA [insulin glulisine injection (rDNA origin)] is a recombinant human basal insulin analogue to maintain adequate glucose control (see DOSAGE AND . Apidra SoloStar Units/ml solution for injection in a pre-filled pen . SoloStar, the Instructions for use included in the Package leaflet must be read carefully. Package leaflet: Information for the user. Apidra® SoloStar®. Units/ml solution for injection in a pre-filled pen insulin glulisine. Talk to your doctor.
Oh, Snap! The Asante Pearl will now be known as the Asante Snap, a pretty spot-on name since it's not only short and snappy pun intended! Yes, it pops apart into two main pieces: a main controller with screen and buttons, and a disposal body portion that contains a pre-filled cartridge that can be thrown out after the insulin is used up. Created by Asante Solutions based in Sunnyvale, CA, this pump's quick and easy snap design is aimed at giving us PWDs people with diabetes a device that means "less prep time, more lifetime. In early January, we chatted with Asante execs about what they've been up to since their insulin pump received FDA approval in May Their pump was the first device to get through the federal agency's more stringent guidelines for insulin pumps, but since then they've been working quietly behind the scenes in preparation of their upcoming mid launch.
Furthermore, a survey of 1, diabetic patients suggested that decreased blood glucose monitoring compliance was observed in patients who had more than two hospitalizations in a 2-year period. Yet, despite current evidence of the importance of daily SMBG, many patients who have diabetes do not regularly check their blood glucose at home. Hence, some patients choose to avoid these unpleasant aspects by simply not checking blood sugars on a regular basis, especially since hyperglycemia is often asymptomatic in the early stages of diabetes mellitus.
In addition to the difficulties posed by SMBG, maintaining proper glycemic control can be a challenge, especially for patients who are on insulin therapy. Patients who use short-acting insulin to help control blood glucose during a meal must constantly estimate their insulin doses by counting the carbohydrate content of the meal. Since most of us do not eat the same meal every day for breakfast, lunch, and dinner, counting carbohydrates can become a cumbersome process.
Furthermore, improperly estimating an insulin dose can potentially result in undertreatment or overtreatment, which may have grave consequences. Based on discharge data of Californian hospitals, hypoglycemia was found to be responsible for approximately 1.
Controlling blood sugar with fast-acting insulin is difficult because it poses the risk of hypoglycemia or hyperglycemia if insulin is not administered in a correct manner.
It is difficult to estimate the amount of insulin required with varying portion sizes and fluctuating sugar levels throughout the day.
In contrast to type 2 DM, a long asymptomatic period of hyperglycemia is rare prior to the diagnosis of type 1 DM. A number of immunologic markers for type 1 DM are becoming available, but their routine use is discouraged pending the identification of clinically beneficial interventions for individuals at high risk for developing type 1 DM.
However, the colours were difficult to visualise as the colour blocks were affected by ambient lighting conditions, and variation in individual visual acuity made it difficult to obtain accurate and precise readings.
Around the same time, the German company Boehringer Mannheim developed a competitive blood glucose strip, the Chemstrip bG. This was easier to use because the drop of blood was wiped off using a cotton wool ball, and, as it had a dual colour pad one beige, the other blue , it was easier to visualise the colour.
The visually monitored blood glucose test strips, Dextrostix Ames and Chemstrip bG Boehringer Mannheim , were widely used in clinics, surgeries and hospital wards, notably intensive care units, for adults and neonates. However, colours were prone to fade and it was realised that there were highly significant visual variations in the assessment of colours across the range of glucose concentrations using Dextrostix.
These limitations became the trigger to develop an automatic, electronic glucose test strip reader to improve precision and give more quantitative blood glucose results. The development in the s of the oxygen electrode by Clarke for the measurement of pO2 was the forerunner in the development of the first biosensor electrode. The first description of a biosensor, an amperometric enzyme method for glucose measurement, was made by Clarke and Lyons in The first blood glucose biosensor system, the ExacTech, was launched in by MediSense.
It used an enzyme electrode strip developed in the UK at Cranford and Oxford universities. The strip contained glucose oxidase and an electron transfer mediator, ferrocene, which replaced oxygen in the original glucose oxidase reaction; the reduced mediator was reoxidised at the electrode to generate a current detected by an amperometric sensor.
The meter was available in two highly original forms, a slim pen or a thin card the size of a credit card. Evaluation reports showed that accuracy, precision and error grid analysis were satisfactory.
The use of electrode technology thus heralded what became designated the third-generation BGMS. A useful evaluation statistical tool, error grid analysis, was developed by Clarke et al.
Sample sizes vary from 30 to 0. Test times vary from 5 seconds to 2 minutes modern meters typically provide results in 5 seconds. Historically, blood glucose values were given in terms of whole blood, but most laboratories now measure and report plasma or serum glucose levels.
Because red blood cells erythrocytes have a higher concentration of protein e. To convert from whole-blood glucose, multiplication by 1. Collection of blood in clot tubes for serum chemistry analysis permits the metabolism of glucose in the sample by blood cells until separated by centrifugation. Red blood cells, for instance, do not require insulin to intake glucose from the blood. Higher than normal amounts of white or red blood cell counts can lead to excessive glycolysis in the sample, with substantial reduction of glucose level if the sample is not processed quickly.
At refrigerator temperatures, glucose remains relatively stable for several hours in a blood sample.
Loss of glucose can be prevented by using Fluoride tubes i. However, these should only be used when blood will be transported from one hospital laboratory to another for glucose measurement. Red-top serum separator tubes also preserve glucose in samples after being centrifuged isolating the serum from cells.
Not at this point, El-Sherif says. But Asante isn't even interested in following suit of other device makers by "creating our own software you have to buy or learn to use separately. To that we say: Nice move, Asante! Customer Needs Over Profit?! Asante plans to offer a day trial period for anyone looking to buy this new pump, he said. They're promising no hassle, no questions as to why, no timelines that you have to think about -- just a "snap," as the company marketing points out. We want people to know what they are buying and feel comfortable with it first, and that we appreciate them staying with us.
How about that?!
A medical device company looking first to do what's best for customers, and letting the profits fall where they may. Bravo, Asante!
Now, I haven't used this pump or held it in my hand. And I'm not quite sure about the whole "Humalog only" aspect of this pump.
Some endocrinologists and educators in the U. But from what I've seen of the design and heard about their customer policies, I'm eager to try the Snap pump if the chance arises! What do you think?
A penny for your thoughts, existing pumpers? Ready, Set, Snap! Tell your doctor about other medicines and supplements you are taking because they can change the way insulin works.
Before starting Lantus, tell your doctor about all your medical conditions including if you have liver or kidney problems, are pregnant or planning to become pregnant, or are breast-feeding or planning to breast-feed. Please talk to your healthcare provider about proper injection technique and follow instructions in the Instruction Leaflet that accompanies the pen. It should be taken once a day at the same time each day to lower blood glucose.
Do not use Lantus to treat diabetic ketoacidosis. Please click here for full prescribing information for Lantus.
Apidra, when given by injection under the skin, should not be mixed with insulins other than NPH. Do not mix Apidra with any insulin when used in the pump or for intravenous administration. The most common side effect of insulin, including Apidra, is low blood sugar hypoglycemia , which may be serious.
Other possible side effects may include low blood potassium, injection site reactions, such as changes in fat tissue at the injection site, and allergic reactions, such as itching and rash.